Singapore markets closed
Straits Times Index
3,338.57 +5.77 (+0.17%) S&P 500
5,460.48 -22.39 (-0.41%) Dow
39,118.86 -45.24 (-0.12%) Nasdaq
17,732.60 -126.10 (-0.71%) Bitcoin USD
62,825.05 +1,377.94 (+2.24%) CMC Crypto 200
1,304.65 +2.58 (+0.20%)
ITCI Dec 2025 60.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 11:33AM EDT. Market open.
| Previous close | 8.50 |
| Open | 8.50 |
| Bid | 6.10 |
| Ask | 10.50 |
| Strike | 60.00 |
| Expiry date | 2025-12-19 |
| Day's range | 8.50 - 8.50 |
| Contract range | N/A |
| Volume | |
| Open interest | 351 |
ZacksIntra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
ZacksBiotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
ZacksIntra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
© 2024 Yahoo. All rights reserved.